Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Other disposition IA/Managing Member of 10% Owne disposed of 4,338 shares (other)
  4. 4/A Open-market buy IA/Managing Member of 10% owne bought 4,965 shares at an average $25.35 ($125,863)
  5. 4/A Open-market buy IA/Managing Member of 10% owne bought 2,800 shares at an average $26.46 ($74,100)
  6. 4/A Open-market buy IA/Managing Member of 10% owne bought 8,600 shares at an average $26.98 ($232,056)
  7. 3/A Insider 3/A
  8. 4 Open-market buy IA/Managing Member 10% owner bought 4,965 shares at an average $25.35 ($125,863)
  9. 4 Open-market buy IA/Managing Member 10% owner bought 2,800 shares at an average $26.46 ($74,100)
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market buy IA/Managing Member 10% owner bought 8,600 shares at an average $26.98 ($232,056)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Open-market buy 10% owner bought 50,000 shares at $17.00 ($850,000)
  14. 4 Conversion 10% owner acquired 2,679,802 shares (conversion)
  15. 4 Conversion 10% owner acquired 2,886,530 shares (conversion)
  16. 4 Conversion Director acquired 1,925,165 shares (conversion)
  17. 4 Derivatives Options or other derivatives
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 10 of 11 · 211 filings